Production.

Sinopharm Group Chairman and Party Secretary Liu Jingzhen said that as of December 2020, the two inactivated vaccines of the Beijing Institute of Biological Products and the Wuhan Institute of Biological Products, both affiliated to Sinopharm China Biologics, are being distributed in the United Arab Emirates and Paris. Phase III clinical trials have been carried out in 10 countries including Jordan, Peru, Argentina and Egypt. More than 50,000 people have been vaccinated, and the total number of people vaccinated will reach more than 60,000. The sample size of the vaccinated population covers 125 nationalities. The progress in all aspects leads the world and has been widely recognized internationally. Dozens of countries have requested COVID-19 vaccines from Sinopharm China Biotech.

According to Liu Jingzhen, on February 1, Sinopharm China Biotech, as the leading unit, received the key special inactivated vaccine from the Ministry of Science and Technology’s national key research and development program "Public Safety Risk Prevention and Control and Emergency Technical Equipment" Emergency approval of the project. On April 12, the COVID-19 inactivated vaccine developed by Wuhan Institute of Biological Products received clinical trial approval and simultaneously launched domestic Phase I/II clinical trials. On April 27, the inactivated COVID-19 vaccine developed by the Beijing Institute of Biological Products once again received clinical trial approval, adding double insurance to the research and development of the COVID-19 vaccine.

In the domestic phase I/II clinical study, 4064 people of all ages were included in the group. The unblinded results showed that the vaccine was safe after vaccination. Different ages, different procedures, and different doses of vaccination Both vaccines produced high-titer immune responses. After two doses of the two vaccines were administered according to the 0 and 28-day schedule, the neutralizing antibody seroconversion rate reached 100%.

Extended information:

Since the outbreak of the new coronavirus pneumonia, the Party Central Committee and the State Council have attached great importance to vaccine research and development, and China has quickly launched a vaccine research and development plan. In accordance with the unified deployment, emergency scientific research is accelerated along five vaccine technology routes - inactivated vaccines, recombinant protein vaccines, adenovirus vector vaccines, live attenuated influenza virus vector vaccines, and nucleic acid vaccines.

“As a central enterprise whose main business is the pharmaceutical and health industry, Sinopharm Group has undertaken the important scientific research tasks of two technical routes: inactivated vaccine and recombinant protein during the research and development process of the new crown vaccine.” Liu Jingzhen said, On January 19, Sinopharm Group allocated 1 billion yuan in R&D funds and established a scientific research leadership group led by Yang Xiaoming, chief scientist of the Ministry of Science and Technology’s “863” program vaccine project and chairman of Sinopharm China Biotech, and deployed three research institutes and institutes. New coronavirus vaccine research and development is carried out on two technical routes.

Reference materials: People’s Health Network-Chairman of Sinopharm Group: Two new crown inactivated vaccines have been vaccinated for more than 50,000 people